GZC8072 / Gan & Lee Pharma - LARVOL DELTA

A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: Gan & Lee Pharmaceuticals. | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

Gan&Lee Pharmaceuticals…announced that the first participant has been dosed in a First-In-Human (FIH) Phase 1 study of GZC8072 tablets, a novel ultra-long-acting oral peptide GLP-1 RA formulated for once-weekly administration (PRNewswire) - "The study is a multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase 1 study (CTR20263271), designed to evaluate the safety and tolerability of GZC8072 in healthy adult participants in the single ascending dose (SAD) portion and in participants with overweight or obesity in the multiple ascending dose (MAD) portion. A total of 112 participants are planned for enrollment, and will receive either GZC8072 tablets or matching placebo."

First-in-human • Trial status • Obesity

A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants (clinicaltrials.gov) - P1 | N=112 | Not yet recruiting | Sponsor: Gan & Lee Pharmaceuticals.

New P1 trial • Genetic Disorders • Obesity